BRIEF—Yescarta label updated to include use of prophylactic corticosteroids

The US Food and Drug Administration (FDA) has approved an update to the prescribing information for Yescarta (axicabtagene ciloleucel) to include use of prophylactic corticosteroids across all approved indications.

This updated toxicity management strategy can improve certain adverse events without compromising the activity of Yescarta, it is believed.

With this update, the Gilead Sciences drug becomes the first chimeric antigen receptor (CAR) T-cell therapy with information in the label to help physicians manage, and potentially prevent, treatment side effects.

Yescarta was the first CAR T-cell therapy to be approved by the FDA for the treatment of adults with relapsed or refractory large B-cell lymphoma (LBCL) after two or more lines of systemic therapy. It is also currently under review in the USA and European Union for use as an earlier treatment of patients with second-line relapsed or refractory LBCL.